Drug intelligence / Profile preview

Shenqi Dihuang decoction

Development stage: Phase 1
Lead developer: Zhejiang Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Shenqi Dihuang decoction is a Traditional Chinese Medicine (TCM) formula primarily used for the treatment of chronic kidney diseases, specifically IgA nephropathy. It is designed to supplement Qi and nourish Yin. In clinical research conducted by the Zhejiang Provincial Hospital of Traditional Chinese Medicine, it is being evaluated for its effects on the ACE2–Ang(1-7)–Mas axis, reduction of oxidative stress, and management of proteinuria in patients with IgA nephropathy (CKD stages 1–4). The formula typically contains ingredients such as *Astragalus membranaceus* (Huangqi) and *Rehmannia glutinosa* (Dihuang).

Other names: Shenqi Dihuang TangShen-Qi-Di-Huang Decoction

Targets

ACE2 (Angiotensin-converting enzyme 2)

Beyond the preview

Go deeper on Shenqi Dihuang decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenqi Dihuang decoction.

Explore the full profile